{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:43:01Z","timestamp":1792557781948,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2019ZX09301126"],"award-info":[{"award-number":["2019ZX09301126"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2019JZZY021011"],"award-info":[{"award-number":["2019JZZY021011"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973181"],"award-info":[{"award-number":["81973181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.apsb.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T11:49:50Z","timestamp":1611143390000},"page":"3035-3059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Recent developments in the medicinal chemistry of single boron atom-containing compounds"],"prefix":"10.1016","volume":"11","author":[{"given":"Shu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kongsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanthanathan","family":"Poongavanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7882","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.01.010_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2533\/chimia.2019.207","article-title":"International year of the periodic table 2019: elements important for life sciences","volume":"73","author":"Albertoa","year":"2019","journal-title":"Chimia"},{"key":"10.1016\/j.apsb.2021.01.010_bib2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron-containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4155\/fmc.13.38","article-title":"Boron chemicals in diagnosis and therapeutics","volume":"5","author":"Das","year":"2013","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","article-title":"Boron in drug design: Recent advances in the development of new therapeutic agents","volume":"179","author":"Fernandes","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib5","first-page":"1118","article-title":"The fifth element in drug design: Boron in medicinal chemistry","volume":"66","author":"Kahlert","year":"2013","journal-title":"ChemInform"},{"key":"10.1016\/j.apsb.2021.01.010_bib6","first-page":"361","article-title":"Bortezomib (PS-341):\u00a0A novel, first-in-class proteasome inhibitor for the treatment of\u00a0multiple myeloma and other cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Contr"},{"key":"10.1016\/j.apsb.2021.01.010_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/17512433.2016.1206467","article-title":"Tavaborole\u2014a treatment for onychomycosis of the toenails","volume":"9","author":"Gupta","year":"2016","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.apsb.2021.01.010_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.apsb.2021.01.010_bib9","first-page":"390","article-title":"Crisaborole topical ointment, 2%: A nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis","volume":"15","author":"Jarnagin","year":"2016","journal-title":"J Drugs Dermatol JDD"},{"key":"10.1016\/j.apsb.2021.01.010_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425255.2018.1511702","article-title":"Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection","volume":"14","author":"Burgos","year":"2018","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.apsb.2021.01.010_bib11","series-title":"ChEMBL database","year":"2020"},{"key":"10.1016\/j.apsb.2021.01.010_bib12","series-title":"Talabostat and pembrolizumab for the treatment of advanced solid cancers. ClinicalTrials.gov. Identifier: NCT04171219","year":"2019"},{"key":"10.1016\/j.apsb.2021.01.010_bib13","series-title":"Study of dutogliptin in combination with filgrastim\u00a0in\u00a0post-myocardial infarction. ClinicalTrials.gov. Identifier:\u00a0NCT03486080","author":"Recardio, Inc","year":"2018"},{"key":"10.1016\/j.apsb.2021.01.010_bib14","series-title":"An early bactericidal activity, safety and tolerability of GSK3036656 in subjects with drug-sensitive pulmonary tuberculosis. ClinicalTrials.gov. Identifier: NCT03557281","author":"GlaxoSmithKline","year":"2018"},{"key":"10.1016\/j.apsb.2021.01.010_bib15","series-title":"Prospective study on efficacy and safety of acoziborole (SCYX-7158) in patients infected by human African trypanosomiasis due to T.b. Gambiense (OXA002). ClinicalTrials.gov. Identifier: NCT03087955","author":"Drugs for Neglected Diseases","year":"2017"},{"key":"10.1016\/j.apsb.2021.01.010_bib16","series-title":"Efficacy and safety of AN2898 and AN2728 topical ointments to treat mild-to-moderate atopic dermatitis. ClinicalTrials.gov. Identifier: NCT01301508","author":"Pfizer","year":"2011"},{"key":"10.1016\/j.apsb.2021.01.010_bib17","series-title":"Safety and efficacy study of cefepime\/VNRX-5133 in patients with complicated urinary tract infections. ClinicalTrials.gov. Identifier: NCT03840148","author":"VenatoRx Pharmaceuticals, Inc","year":"2019"},{"key":"10.1016\/j.apsb.2021.01.010_bib18","series-title":"P1 single and multiple ascending dose (SAD\/MAD) study of IV QPX7728 alone and combined with QPX2014 in NHV. ClinicalTrials.gov. Identifier: NCT04380207","author":"Qpex Biopharma, Inc","year":"2020"},{"key":"10.1016\/j.apsb.2021.01.010_bib19","series-title":"Study to assess the safety, pharmacokinetics, and antiviral activity of repeat doses of GSK2878175 in subjects with chronic hepatitis C. ClinicalTrials.gov. Identifier: NCT02014571","author":"GlaxoSmithKline","year":"2013"},{"key":"10.1016\/j.apsb.2021.01.010_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nchem.2814","article-title":"The versatility of boron in biological target engagement","volume":"9","author":"Diaz","year":"2017","journal-title":"Nat Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib21","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1021\/acs.jmedchem.7b00952","article-title":"Stilbene boronic acids form a covalent bond with human transthyretin and inhibit its aggregation","volume":"60","author":"Smith","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2021.01.010_bib23","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.apsb.2021.01.010_bib24","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1038\/ncomms7561","article-title":"Targeting bacteria via iminoboronate chemistry of amine-presenting lipids","volume":"6","author":"Bandyopadhyay","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.01.010_bib25","doi-asserted-by":"crossref","first-page":"14015","DOI":"10.1021\/jacs.8b07366","article-title":"Sub-picomolar inhibition of HIV-1 protease with a boronic acid","volume":"140","author":"Windsor","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib26","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/acs.jmedchem.8b01719","article-title":"Design of N-benzoxaborole benzofuran GSK8175-optimization of human pharmacokinetics inspired by metabolites of a failed clinical HCV inhibitor","volume":"62","author":"Chong","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib27","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","article-title":"Discovery of taniborbactam (VNRX-5133): A broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib28","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1039\/c2cs35435g","article-title":"Binding sugars: From natural lectins to synthetic receptors and engineered neolectins","volume":"42","author":"Arnaud","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2021.01.010_bib29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/anie.199619101","article-title":"Saccharide sensing with molecular receptors based on boronic acid","volume":"35","author":"James","year":"1996","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2021.01.010_bib30","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/jo01370a013","article-title":"Areneboronates from diols and polyols","volume":"19","author":"Kuivila","year":"1954","journal-title":"J Org Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1039\/C2AN36048A","article-title":"Fine-tuning the specificity of boronate affinity monoliths toward glycoproteins through pH manipulation","volume":"138","author":"Lu","year":"2013","journal-title":"Analyst"},{"key":"10.1016\/j.apsb.2021.01.010_bib32","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1039\/C9SC00415G","article-title":"Targeting extracellular glycans: Tuning multimeric boronic acids for pathogen-selective killing of Mycobacterium tuberculosis","volume":"10","author":"Guy","year":"2019","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2021.01.010_bib33","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","article-title":"Fulvestrant-3 boronic acid (ZB716): An orally bioavailable selective estrogen receptor downregulator (SERD)","volume":"59","author":"Liu","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-015-3461-9","article-title":"Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer","volume":"152","author":"Zhang","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.apsb.2021.01.010_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s12885-015-1621-2","article-title":"Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status","volume":"15","author":"Zhong","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apsb.2021.01.010_bib36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.chembiol.2010.09.008","article-title":"Assembling ligands in situ using bioorthogonal boronate ester synthesis","volume":"17","author":"Shin","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib37","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1002\/anie.201202000","article-title":"Dynamic combinatorial chemistry employing boronic acids\/boronate esters leads to potent oxygenase inhibitors","volume":"51","author":"Demetriades","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2021.01.010_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121793","article-title":"Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in Myc over-expressing cancer cell lines","volume":"10","author":"Wanner","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.01.010_bib39","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1021\/ja01578a020","article-title":"Electrophilic Displacement Reactions. IX. Effects of substituents on rates of reactions between hydrogen peroxide and benzeneboronic acid1-3","volume":"79","author":"Kuivila","year":"1957","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/acsmedchemlett.7b00504","article-title":"Biocompatible boron-containing prodrugs of belinostat for the potential treatment of solid tumors","volume":"9","author":"Zheng","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.01.010_bib41","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1021\/jm400754c","article-title":"Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells","volume":"56","author":"Marzenell","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib42","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1021\/acs.jmedchem.5b01932","article-title":"Challenges and opportunities for the application of boron clusters in drug design","volume":"59","author":"Le\u015bnikowski","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2017.1252750","article-title":"Boron's journey: Advances in the study and application of pharmacokinetics","volume":"27","author":"Ocampo-N\u00e9stor","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2021.01.010_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejmech.2008.02.037","article-title":"Promising carboranylquinazolines for boron neutron capture therapy: Synthesis, characterization, and in\u00a0vitro toxicity evaluation","volume":"44","author":"Genady","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib45","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2021.01.010_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression\u2014implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2021.01.010_bib47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2021.01.010_bib48","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1042\/BST20140126","article-title":"Overcoming bortezomib\u00a0resistance in multiple myeloma","volume":"42","author":"Murray","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.apsb.2021.01.010_bib49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood-2009-07-235663","article-title":"Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma","volume":"116","author":"Kikuchi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2021.01.010_bib50","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/acs.jmedchem.9b02161","article-title":"Discovery of peptide boronate derivatives as histone deacetylase and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma","volume":"63","author":"Zhou","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib51","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1038\/oncsis.2015.10","article-title":"Human dCTP pyrophosphatase 1 promotes breast cancer cell growth and stemness through the modulation on 5-methyl-dCTP metabolism and global hypomethylation","volume":"4","author":"Song","year":"2015","journal-title":"Oncogenesis"},{"key":"10.1016\/j.apsb.2021.01.010_bib52","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acs.jmedchem.5b01741","article-title":"Discovery of the first potent and selective inhibitors of human dCTP pyrophosphatase 1","volume":"59","author":"Llona-Minguez","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib53","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/acschembio.8b00124","article-title":"The role of ClpP protease in bacterial pathogenesis and human diseases","volume":"13","author":"Bhandari","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib54","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ccell.2015.05.004","article-title":"Inhibition of the mitochondrial protease ClpP as a therapeutic strategy\u00a0for human acute myeloid leukemia","volume":"27","author":"Cole","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.01.010_bib55","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1074\/jbc.M114.625640","article-title":"Cleavage specificity of Mycobacterium tuberculosis ClpP1P2 protease and identification of novel peptide substrates and boronate inhibitors with anti-bacterial activity","volume":"290","author":"Akopian","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib56","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1021\/acs.jmedchem.9b00878","article-title":"De novo design of boron-based peptidomimetics as potent inhibitors of human ClpP in the presence of human ClpX","volume":"62","author":"Tan","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib57","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1021\/jacs.5b03084","article-title":"Phenyl esters are potent inhibitors of caseinolytic protease P and reveal a stereogenic switch for deoligomerization","volume":"137","author":"Hackl","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nchembio.2174","article-title":"Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain","volume":"12","author":"Ak\u00e7ay","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib59","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1021\/jacs.8b02279","article-title":"Versatile histochemical approach to detection of hydrogen peroxide in cells and tissues based on puromycin staining","volume":"140","author":"Yik-Sham Chung","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib60","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1039\/C5SC03488D","article-title":"Stimuli-responsive colorimetric and NIR fluorescence combination probe for selective reporting of cellular hydrogen peroxide","volume":"7","author":"Narayanaswamy","year":"2016","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2021.01.010_bib61","doi-asserted-by":"crossref","first-page":"112670","DOI":"10.1016\/j.ejmech.2020.112670","article-title":"Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironmol\/Lent","volume":"207","author":"Maslah","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib62","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1021\/jm401349g","article-title":"Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes","volume":"57","author":"Chen","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib63","doi-asserted-by":"crossref","first-page":"9132","DOI":"10.1021\/acs.jmedchem.8b00559","article-title":"Discovery and optimization of novel hydrogen peroxide activated aromatic nitrogen mustard derivatives as highly potent anticancer agents","volume":"61","author":"Chen","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7150\/thno.5411","article-title":"Superparamagnetic iron oxide nanoparticles: Amplifying ROS stress to improve anticancer drug efficacy","volume":"3","author":"Huang","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2021.01.010_bib65","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.01.010_bib66","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1021\/jm2014937","article-title":"Aminoferrocene-based prodrugs activated by reactive oxygen species","volume":"55","author":"Hagen","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib67","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1074\/jbc.M309708200","article-title":"2\u2032-Benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species","volume":"279","author":"Han","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib68","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1038\/ncomms7907","article-title":"Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death","volume":"6","author":"Noh","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.01.010_bib69","first-page":"263","article-title":"Molecular imaging of hydrogen peroxide produced for cell signaling","volume":"5","author":"Miller","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib70","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1002\/anie.201203222","article-title":"Hydrogen peroxide induced activation of gene expression in mammalian cells using boronate estrone derivatives","volume":"51","author":"Govan","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2021.01.010_bib71","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1073\/pnas.1424684112","article-title":"Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates","volume":"112","author":"Chou","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.01.010_bib72","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1021\/acs.jmedchem.9b00736","article-title":"Design, synthesis, and structure\u2012activity relationship of 7-propanamide benzoxaboroles as potent anticancer agents","volume":"62","author":"Zhang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10147-019-01480-4","article-title":"Boron neutron capture therapy (BNCT): A unique role in radiotherapy with a view to entering the accelerator-based BNCT era","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.apsb.2021.01.010_bib74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2011.02.008","article-title":"Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement","volume":"99","author":"Kankaanranta","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.apsb.2021.01.010_bib75","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.ijrobp.2010.09.057","article-title":"Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I\/II trial","volume":"82","author":"Kankaanranta","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.apsb.2021.01.010_bib76","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1118\/1.3218760","article-title":"First application of dynamic infrared imaging in boron neutron capture therapy for cutaneous malignant melanoma","volume":"36","author":"Santa Cruz","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.apsb.2021.01.010_bib77","first-page":"861","article-title":"Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis","volume":"18","author":"Ariyoshi","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.apsb.2021.01.010_bib78","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1021\/acs.molpharmaceut.0c00630","article-title":"Addressing the biochemical foundations of a glucose-based \"trojan horse\"-strategy to boron neutron capture therapy: From chemical synthesis to in\u00a0vitro assessment","volume":"17","author":"Matovi\u0107","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.01.010_bib79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rpor.2014.11.004","article-title":"Present status of accelerator-based BNCT","volume":"21","author":"Kreiner","year":"2016","journal-title":"Rep Practical Oncol Radiother"},{"key":"10.1016\/j.apsb.2021.01.010_bib80","doi-asserted-by":"crossref","first-page":"109029","DOI":"10.1016\/j.apradiso.2019.109029","article-title":"Boron neutron capture therapy at the crossroads\u2014where do we go from here?","volume":"160","author":"Barth","year":"2020","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.apsb.2021.01.010_bib81","first-page":"35","article-title":"Boron delivery agents for neutron capture therapy of cancer","volume":"38","author":"Barth","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.apsb.2021.01.010_bib82","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2015.01.048","article-title":"Folate-grafted boron nitride nanotubes: possible exploitation in cancer therapy","volume":"481","author":"Ferreira","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.01.010_bib83","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.2174\/0929867324666170918122633","article-title":"Design and discovery of new antibacterial agents: Advances, perspectives, challenges","volume":"25","author":"Jampilek","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib84","series-title":"Global tuberculosis report 2019","author":"WHO","year":"2020"},{"key":"10.1016\/j.apsb.2021.01.010_bib85","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cbpa.2019.03.001","article-title":"Will morphing boron-based inhibitors beat the \u03b2-lactamases?","volume":"50","author":"Krajnc","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib86","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant \u03b2-lactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2021.01.010_bib87","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbagen.2019.02.004","article-title":"Studies on the inhibition of AmpC and other \u03b2-lactamases by cyclic boronates","volume":"1863","author":"Cahill","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.apsb.2021.01.010_bib88","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/ja0288338","article-title":"Nanomolar inhibitors of AmpC beta-lactamase","volume":"125","author":"Morandi","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib89","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1021\/acs.jmedchem.5b00341","article-title":"Click chemistry in lead optimization of boronic acids as \u03b2-lactamase inhibitors","volume":"58","author":"Caselli","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib90","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of acinetobacter infections: A century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.apsb.2021.01.010_bib91","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1021\/acsinfecdis.0c00254","article-title":"1,2,3-Triazolylmethaneboronate: a structure activity relationship study of a class of \u03b2-lactamase inhibitors against Acinetobacter baumannii cephalosporinase","volume":"6","author":"Caselli","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2021.01.010_bib92","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1021\/bi992505b","article-title":"Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-lactamase","volume":"39","author":"Ness","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2021.01.010_bib93","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib94","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1038\/ncomms12406","article-title":"Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates","volume":"8","author":"Brem","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.01.010_bib95","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","article-title":"Bicyclic boronate VNRX-5133 inhibits metallo- and serine-\u03b2-lactamases","volume":"62","author":"Krajnc","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib96","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1021\/acs.jmedchem.9b01976","article-title":"Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-\u03b2-lactamases","volume":"63","author":"Hecker","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib97","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1021\/acs.jmedchem.9b00735","article-title":"Structure-based development of (1-(3\u2032-mercaptopropanamido)methyl)boronic acid derived broad-spectrum, dual-action inhibitors of metallo- and serine-\u03b2-lactamases","volume":"61","author":"Wang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib98","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1128\/AAC.00820-16","article-title":"Antimalarial benzoxaboroles target plasmodium falciparum leucyl-tRNA synthetase","volume":"60","author":"Sonoiki","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.01.010_bib99","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib100","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1021\/acs.jmedchem.9b01746","article-title":"Discovery of novel peptidomimetic boronate ClpP inhibitors with noncanonical enzyme mechanism as potent virulence blockers in\u00a0vitro and in\u00a0vivo","volume":"63","author":"Ju","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib101","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1021\/acs.jmedchem.0c00502","article-title":"Inhibitors of SARS-CoV-2 entry: Current and future opportunities","volume":"63","author":"Xiu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib102","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.apsb.2020.06.002","article-title":"Bioactive natural compounds against human coronaviruses: A review and perspective","volume":"10","author":"Xian","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.01.010_bib103","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.apsb.2020.06.009","article-title":"Combating COVID-19 with integrated traditional Chinese and Western medicine in China","volume":"10","author":"Ni","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.01.010_bib104","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project","volume":"9","author":"Paget","year":"2019","journal-title":"J Glob Health"},{"key":"10.1016\/j.apsb.2021.01.010_bib105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.01.010_bib106","series-title":"Summary of the global HIV epidemic, 2019","author":"WHO","year":"2020"},{"key":"10.1016\/j.apsb.2021.01.010_bib107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20122013: A systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.01.010_bib108","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1021\/jm400317w","article-title":"Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase","volume":"57","author":"Maynard","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib109","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.micinf.2005.12.008","article-title":"Roles of neuraminidase in the initial stage of influenza virus infection","volume":"8","author":"Ohuchi","year":"2006","journal-title":"Microb Infect"},{"key":"10.1016\/j.apsb.2021.01.010_bib110","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.01987-08","article-title":"Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice","volume":"83","author":"Matsuoka","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2021.01.010_bib111","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1039\/c3cc45203d","article-title":"Different cytotoxicities and cellular localizations of novel quindoline derivatives with or without boronic acid modifications in cancer cells","volume":"49","author":"Yin","year":"2013","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.apsb.2021.01.010_bib112","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1021\/acs.jmedchem.6b00326","article-title":"Boronic acid modifications enhance the anti-influenza A virus activities of novel quindoline derivatives","volume":"60","author":"Wang","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib113","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/acs.jmedchem.6b01021","article-title":"Peptide-boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology","volume":"60","author":"Nitsche","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aag2419","article-title":"Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor","volume":"353","author":"Lei","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2021.01.010_bib115","series-title":"World malaria report, 2019","author":"WHO","year":"2020"},{"key":"10.1016\/j.apsb.2021.01.010_bib116","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.01.010_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007722","article-title":"Covalent plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in\u00a0vitro and synergize with multiple antimalarial agents","volume":"15","author":"Stokes","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2021.01.010_bib118","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target validation and identification of novel boronate inhibitors of the plasmodium falciparum proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib119","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1021\/acs.jmedchem.5b00678","article-title":"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles","volume":"98","author":"Zhang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib120","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1021\/acs.jmedchem.7b00621","article-title":"Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate","volume":"60","author":"Zhang","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib121","doi-asserted-by":"crossref","first-page":"21012","DOI":"10.1073\/pnas.1909130116","article-title":"Overcoming insecticide resistance through computational inhibitor design","volume":"116","author":"Correy","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.01.010_bib122","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1039\/C4CC09921D","article-title":"Exploring hydrogen peroxide responsive thiazolidinone-based prodrugs","volume":"51","author":"Perez","year":"2015","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.apsb.2021.01.010_bib123","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1021\/acs.jmedchem.7b01775","article-title":"Synthesis and evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis","volume":"61","author":"Peir\u00f3 Cadah\u00eda","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nchembio0605-13","article-title":"Chemistry in living systems","volume":"1","author":"Prescher","year":"2005","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib125","doi-asserted-by":"crossref","first-page":"16793","DOI":"10.1073\/pnas.0707090104","article-title":"Copper-free click chemistry for dynamic in\u00a0vivo imaging","volume":"104","author":"Baskin","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.01.010_bib126","doi-asserted-by":"crossref","first-page":"11486","DOI":"10.1021\/ja803086r","article-title":"Second-generation difluorinated cyclooctynes for copper-free click chemistry","volume":"130","author":"Codelli","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib127","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/bc0000942","article-title":"Phenylboronic acid-salicylhydroxamic acid bioconjugates. 1. A novel boronic acid complex for protein immobilization","volume":"12","author":"Stolowitz","year":"2001","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib128","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.pharmthera.2014.01.004","article-title":"Targeting mast cells in inflammatory diseases","volume":"142","author":"Reber","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2021.01.010_bib129","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1021\/acs.jmedchem.9b01689","article-title":"Novel, self-assembling dimeric inhibitors of human \u03b2 tryptase","volume":"63","author":"Giardina","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib130","doi-asserted-by":"crossref","first-page":"15780","DOI":"10.1021\/jacs.0c05261","article-title":"Controlled supramolecular assembly inside living cells by sequential multi-staged chemical reactions","volume":"142","author":"Pieszka","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.01.010_bib131","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1021\/acs.bioconjchem.8b00358","article-title":"\"Tag and Modify\" protein conjugation with dynamic covalent chemistry","volume":"29","author":"Zegota","year":"2018","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2021.01.010_bib132","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtemb.2014.06.023","article-title":"Update on human health effects of boron","volume":"28","author":"Nielsen","year":"2014","journal-title":"J Trace Elem Med Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib133","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nchembio.1666","article-title":"Covalent docking of large libraries for the discovery of chemical probes","volume":"10","author":"London","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2021.01.010_bib134","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1039\/C4CC09107H","article-title":"Facile synthesis of borofragments and their evaluation in activity-based protein profiling","volume":"51","author":"Adachi","year":"2015","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.apsb.2021.01.010_bib135","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1039\/C9CS00184K","article-title":"Boronic acids as building blocks for the construction of therapeutically useful bioconjugates","volume":"48","author":"Ant\u00f3nio","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2021.01.010_bib136","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1021\/cr500642d","article-title":"Recent developments in the chemistry and biological applications of benzoxaboroles","volume":"115","author":"Adamczyk-Wo\u017aniak","year":"2015","journal-title":"Chem Rev"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:05Z","timestamp":1761929465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":136,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2211383521000137"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.01.010","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in the medicinal chemistry of single boron atom-containing compounds","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}